• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型窦房结调节剂S 16257对兔和豚鼠心脏标本的电生理效应:与UL-FS 49的比较

Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49.

作者信息

Thollon C, Cambarrat C, Vian J, Prost J F, Peglion J L, Vilaine J P

机构信息

Division Pathologies Cardiaques et Vasculaires, Institut de Recherches Servier, Suresnes, France.

出版信息

Br J Pharmacol. 1994 May;112(1):37-42. doi: 10.1111/j.1476-5381.1994.tb13025.x.

DOI:10.1111/j.1476-5381.1994.tb13025.x
PMID:8032660
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1910295/
Abstract
  1. S 16257 is a new bradycardic agent. Its electropharmacological profile has been compared to that of the known bradycardic compound UL-FS 49 (Zatebradine). Intracellular recordings of action potentials (APs) were performed with conventional glass microelectrodes. 2. In the rabbit isolated sino-atrial node (SAN) tissue, S 16257 and UL-FS 49 (1 microM, 3 microM and 10 microM) were equipotent in slowing spontaneous APs firing predominantly by decreasing the rate of diastolic depolarization (at 3 microM, -23.8 +/- 3.9% and -27.9 +/- 2.6%, respectively). For the two compounds a maximal effect was obtained at 3 microM. In these preparations, action potential duration at 50% of total repolarization (APD50) was more affected by UL-FS 49 than S 16257 at any concentration tested (at 3 microM, +8.9 +/- 2.9% and +29.1 +/- 3.7% for S 16257 and UL-FS 49, respectively; P < or = 0.01). 3. To estimate the direct effects on AP duration, driven cardiac preparations were exposed to these agents. In guinea-pig papillary muscles, paced at a frequency of 1 Hz, increasing concentrations of S 16257 or UL-FS 49 (0.1 to 10 microM, 30 min exposure for each concentration) slightly prolonged AP repolarization. This prolongation was more marked for UL-FS 49 (at 1 microM, +6.1 +/- 0.6% and +11.2 +/- 1.3% elevation of APD50, for S 16257 and UL-FS 49, respectively). 4. Application of UL-FS 49 (3 microM) to rabbit Purkinje fibres, triggered at a frequency of 0.25 Hz, induced a marked prolongation of APD50 and APD90 (+149.4 +/- 51.2% and +86.0 +/- 15.4%, respectively). S 16257 (3 MicroM) induced only a weak prolongation of AP (+ 14.1 +/- 5.0% and + 14.8 +/- 3.3% for APD50 and APD90, respectively) significantly smaller than in the case of UL-FS 49.5. These results show that S 16257 slows the rate of spontaneous AP firing in isolated SAN mainly by a reduction of the diastolic depolarization of the cells, which suggests an inhibition of the pace-maker current (If). S 16257 and UL-FS 49 are equipotent in their bradycardic effect but S 16257 is more specific as it induces less increase in myocardial repolarization time.
摘要
  1. S 16257是一种新型的心动过缓药物。已将其电药理学特征与已知的心动过缓化合物UL-FS 49(扎替雷定)进行了比较。使用传统玻璃微电极进行动作电位(AP)的细胞内记录。2. 在兔离体窦房结(SAN)组织中,S 16257和UL-FS 49(1微摩尔/升、3微摩尔/升和10微摩尔/升)在减慢自发AP发放方面具有等效性,主要是通过降低舒张期去极化速率实现的(在3微摩尔/升时,分别为-23.8±3.9%和-27.9±2.6%)。对于这两种化合物,在3微摩尔/升时可获得最大效应。在这些制剂中,在任何测试浓度下,UL-FS 49对总复极化50%时的动作电位持续时间(APD50)的影响均大于S 16257(在3微摩尔/升时,S 16257和UL-FS 49分别为+8.9±2.9%和+29.1±3.7%;P≤0.01)。3. 为评估对AP持续时间的直接影响,将驱动的心脏制剂暴露于这些药物。在豚鼠乳头肌中,以1赫兹的频率起搏,增加S 16257或UL-FS 49的浓度(0.1至10微摩尔/升,每种浓度暴露30分钟)会使AP复极化略有延长。这种延长在UL-FS 49中更为明显(在1微摩尔/升时,S 16257和UL-FS 49的APD50升高分别为+6.1±0.6%和+11.2±1.3%)。4. 将UL-FS 49(3微摩尔/升)应用于兔浦肯野纤维,以0.25赫兹的频率触发,可导致APD50和APD90显著延长(分别为+149.4±51.2%和+86.0±15.4%)。S 16257(3微摩尔/升)仅使AP有轻微延长(APD50和APD90分别为+14.1±5.0%和+14.8±3.3%),明显小于UL-FS 49的情况。5. 这些结果表明,S 16257主要通过降低细胞的舒张期去极化来减慢离体SAN中自发AP的发放速率,这表明其抑制了起搏电流(If)。S 16257和UL-FS 49在心动过缓作用方面具有等效性,但S 16257更具特异性,因为它引起的心肌复极化时间增加较少。

相似文献

1
Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49.新型窦房结调节剂S 16257对兔和豚鼠心脏标本的电生理效应:与UL-FS 49的比较
Br J Pharmacol. 1994 May;112(1):37-42. doi: 10.1111/j.1476-5381.1994.tb13025.x.
2
Stereospecific in vitro and in vivo effects of the new sinus node inhibitor (+)-S 16257.新型窦房结抑制剂(+)-S 16257的立体特异性体外和体内效应
Eur J Pharmacol. 1997 Nov 19;339(1):43-51. doi: 10.1016/s0014-2999(97)01364-2.
3
Effects of Zeneca ZD7288 in comparison with alinidine and UL-FS 49 on guinea pig sinoatrial node and ventricular action potentials.与阿利尼定和UL-FS 49相比,捷利康ZD7288对豚鼠窦房结和心室动作电位的影响。
J Cardiovasc Pharmacol. 1994 Sep;24(3):380-7. doi: 10.1097/00005344-199409000-00005.
4
On the mechanism of the "specific bradycardic action" of the verapamil derivative UL-FS 49.关于维拉帕米衍生物UL-FS 49“特异性心动过缓作用”的机制
Naunyn Schmiedebergs Arch Pharmacol. 1990 Apr;341(4):331-40. doi: 10.1007/BF00180659.
5
Cardiovascular characterization of UL-FS 49, 1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-][2-(3,4-dimethoxyphenyl)ethyl] methylimino]propyl]-2H-3-benzazepin-2-on hydrochloride, a new "specific bradycardic agent".新型“特异性心动过缓药物”盐酸 UL-FS 49(1,3,4,5-四氢-7,8-二甲氧基-3-[3-][2-(3,4-二甲氧基苯基)乙基]甲基亚氨基]丙基]-2H-3-苯并氮杂卓-2-酮)的心血管特性
Eur J Pharmacol. 1984 Sep 3;104(1-2):9-18. doi: 10.1016/0014-2999(84)90363-7.
6
Electrophysiological effects of EGIS-7229, a new antiarrhythmic agent, in isolated mammalian and human cardiac tissues.新型抗心律失常药物EGIS-7229对离体哺乳动物和人体心脏组织的电生理效应
Naunyn Schmiedebergs Arch Pharmacol. 1997 Mar;355(3):398-405. doi: 10.1007/pl00004960.
7
Effect of pinacidil on the electrophysiological properties in guinea-pig papillary muscle and rabbit sino-atrial node.吡那地尔对豚鼠乳头肌和兔窦房结电生理特性的影响。
J Pharm Pharmacol. 1990 May;42(5):339-43. doi: 10.1111/j.2042-7158.1990.tb05422.x.
8
Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells.心动过缓药物S 16257对兔窦房结细胞离子电流的作用机制
Br J Pharmacol. 1996 Jun;118(4):1051-7. doi: 10.1111/j.1476-5381.1996.tb15505.x.
9
In vitro cardiac electrophysiological effects of prenylamine.普尼拉明的体外心脏电生理效应。
Arch Int Pharmacodyn Ther. 1990 Mar-Apr;304:163-80.
10
Investigations into the bradycardic effects of UL-FS 49 (1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-[[2-(3,4-dimethoxyphenyl)ethyl] methylimino]propyl]-2H-3-benzazepin-2-on-hydrochloride) in isolated guinea pig atria.对盐酸 UL-FS 49(1,3,4,5-四氢-7,8-二甲氧基-3-[3-[[2-(3,4-二甲氧基苯基)乙基]甲基亚氨基]丙基]-2H-3-苯并氮杂卓-2-酮)对离体豚鼠心房的心动过缓作用的研究。
J Cardiovasc Pharmacol. 1986 Jul-Aug;8(4):791-7.

引用本文的文献

1
HCN4 channels sense temperature and determine heart rate responses to heat.HCN4通道感知温度并决定心脏对热的心率反应。
Nat Commun. 2025 Mar 1;16(1):2102. doi: 10.1038/s41467-025-57358-9.
2
Evaluation of efficacy of oral ivabradine for attenuation of hemodynamic response to intubation in hypertensive surgical patients: Effect on rate pressure product as an index of myocardial oxygen demand.评估口服伊伐布雷定对高血压手术患者插管血流动力学反应的衰减效果:以心率血压乘积作为心肌需氧量指标的影响。
J Anaesthesiol Clin Pharmacol. 2024 Oct-Dec;40(4):633-640. doi: 10.4103/joacp.joacp_191_23. Epub 2024 Aug 16.
3
Comparative specialization of intrinsic cardiac neurons in humans, mice and pigs.人类、小鼠和猪内心脏神经元的比较特化
J Physiol. 2025 Mar;603(7):2043-2070. doi: 10.1113/JP286714. Epub 2024 Nov 8.
4
Benzocyclobutenone synthesis exploiting acylsilanes as photofunctional directing groups.利用酰基硅烷作为光功能导向基团的苯并环丁烯酮合成。
Chem Sci. 2024 Oct 25;15(46):19328-35. doi: 10.1039/d4sc05715e.
5
Effect of heart rate control with ivabradine on hemodynamic in patients with sepsis: study protocol for a prospective, multicenter, randomized controlled trial.依伐布雷定控制心率对脓毒症患者血流动力学的影响:一项前瞻性、多中心、随机对照试验的研究方案。
Trials. 2024 Oct 23;25(1):710. doi: 10.1186/s13063-024-08560-5.
6
Structural determinants of ivabradine block of the open pore of HCN4.HCN4 开放孔道中异搏定阻断的结构决定因素。
Proc Natl Acad Sci U S A. 2024 Jul 2;121(27):e2402259121. doi: 10.1073/pnas.2402259121. Epub 2024 Jun 25.
7
Incessant Atrial Tachycardia From the Left Atrial Appendage Treated With Appendage Ligation.经心耳结扎治疗源自左心耳的无休止房性心动过速。
JACC Case Rep. 2024 Jun 4;29(13):102375. doi: 10.1016/j.jaccas.2024.102375. eCollection 2024 Jul 3.
8
Comparative specialization of intrinsic cardiac neurons in humans, mice, and pigs.人类、小鼠和猪心脏内在神经元的比较特化
bioRxiv. 2024 Apr 8:2024.04.04.588174. doi: 10.1101/2024.04.04.588174.
9
Effect of ivabradine on ventricular arrhythmias in heart failure patients with reduced ejection fraction.伊伐布雷定对射血分数降低的心力衰竭患者室性心律失常的影响。
Rev Assoc Med Bras (1992). 2023 Nov 13;69(12):e20230703. doi: 10.1590/1806-9282.20230703. eCollection 2023.
10
The Bradycardic Agent Ivabradine Acts as an Atypical Inhibitor of Voltage-Gated Sodium Channels.心动过缓药物伊伐布雷定作为电压门控钠通道的非典型抑制剂。
Front Pharmacol. 2022 May 2;13:809802. doi: 10.3389/fphar.2022.809802. eCollection 2022.

本文引用的文献

1
Effects of heart rate on coronary flow and cardiac oxygen consumption.心率对冠状动脉血流量和心肌耗氧量的影响。
Am J Physiol. 1956 May;185(2):355-64. doi: 10.1152/ajplegacy.1956.185.2.355.
2
Cardiac pacemaking in the sinoatrial node.窦房结的心脏起搏
Physiol Rev. 1993 Jan;73(1):197-227. doi: 10.1152/physrev.1993.73.1.197.
3
Electrophysiological and inotropic effects of H 234/09 (almokalant) in vitro: a comparison with two other novel IK blocking drugs, UK-68,798 (dofetilide) and E-4031.H 234/09(almokalant)的体外电生理和变力效应:与另外两种新型IK阻断药物UK-68,798(多非利特)和E-4031的比较
Cardiovasc Res. 1993 May;27(5):861-7. doi: 10.1093/cvr/27.5.861.
4
Effects of pacing on triggered activity induced by early afterdepolarizations.起搏对早期后除极所诱发的触发活动的影响。
Circulation. 1984 May;69(5):1013-25. doi: 10.1161/01.cir.69.5.1013.
5
Cardiovascular characterization of UL-FS 49, 1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-][2-(3,4-dimethoxyphenyl)ethyl] methylimino]propyl]-2H-3-benzazepin-2-on hydrochloride, a new "specific bradycardic agent".新型“特异性心动过缓药物”盐酸 UL-FS 49(1,3,4,5-四氢-7,8-二甲氧基-3-[3-][2-(3,4-二甲氧基苯基)乙基]甲基亚氨基]丙基]-2H-3-苯并氮杂卓-2-酮)的心血管特性
Eur J Pharmacol. 1984 Sep 3;104(1-2):9-18. doi: 10.1016/0014-2999(84)90363-7.
6
Effects of alinidine, a novel bradycardic agent, on heart rate and blood pressure in man.新型降心率药物阿利尼定对人体心率和血压的影响。
J Cardiovasc Pharmacol. 1982 Mar-Apr;4(2):213-20. doi: 10.1097/00005344-198203000-00008.
7
Prolongation of the human cardiac monophasic action potential by sotalol.索他洛尔对人心脏单相动作电位的延长作用。
Am J Cardiol. 1982 Nov;50(5):1082-6. doi: 10.1016/0002-9149(82)90421-0.
8
Oxygen consumption of the heart. Newer concepts of its multifactoral determination.心脏的氧消耗。其多因素决定的新概念。
Am J Cardiol. 1968 Sep;22(3):328-36. doi: 10.1016/0002-9149(68)90117-3.
9
Electrophysiologic and voltage clamp analysis of the effects of sotalol on isolated cardiac muscle and Purkinje fibers.索他洛尔对离体心肌和浦肯野纤维作用的电生理及电压钳分析。
J Pharmacol Exp Ther. 1985 Mar;232(3):817-25.
10
Can exercise-induced regional contractile dysfunction be prevented by selective bradycardic agents?选择性心动过缓药物能否预防运动诱发的局部收缩功能障碍?
Naunyn Schmiedebergs Arch Pharmacol. 1986 Dec;334(4):540-3. doi: 10.1007/BF00569399.